Drug Trial Radar · NCT07904052
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Feb 24, 2026
Primary completion
Jul 2029
Study completion Jul 2029
Sponsor
- Lead sponsor
- Inmunotek S.L.Industry
- Sponsor type
- Industry
- Collaborators
- Astrum CRO, S.L.; Eurofins
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn whether EP-088\_MM09 works to treat house dust mite allergy. It will also assess the treatment's safety. EP-088\_MM09 contains modified house dust mite allergens called mannan-conjugated allergoids. The study plans to include 250 participants aged 12 to 65 years. They will have persistent, moderate to severe nasal allergy symptoms, with or without eye symptoms. Participants may also have mild or moderate allergic asthma, provided it is controlled. The main questions are: * Does the treatment lower allergy symptoms and the need for symptom-relief medicines compared with a placebo? * What medical problems or reactions occur during treatment? Researchers will assess how well the treatment works using a score combining symptoms and medication use. The main assessment will cover four weeks after the treatment course. Participants will be assigned by chance to receive either EP-088\_MM09 or a placebo. They will have an equal chance of receiving either treatment. The placebo looks like EP-088\_MM09 but contains no active ingredients. Neither participants nor study doctors will know which treatment each participant receives. Each participant will be in the study for approximately 14 to 21 months. Participants will: * Attend one or two visits before starting treatment to check whether they can take part. * Attend 12 treatment visits, approximately once a month, to receive injections under the skin. They will receive two injections at the first treatment visit and one at each later visit. * Stay at the clinic for at least 30 minutes after each injection. * Record symptoms and medication use daily during specified periods. * Complete questionnaires about their symptoms and quality of life, and provide blood samples. * Attend a final visit about one month after the last treatment visit. Participants who are also sensitive to pollen may need a second visit before starting treatment. This is needed if their first visit falls during the relevant pollen season or within one month before or after it.
Conditions
- Allergic Rhinitis
- Allergic Rhinoconjunctivitis
- Allergic Asthma
Interventions
EP-088_MM09Biological
The composition of the active IMP (EP-088\_MM09) is as follows: * Dermatophagoides pteronyssinus mannan-conjugated (polymerized) allergoid. * Dermatophagoides farinae mannan-conjugated (polymerized) allergoid. The concentration of the Dermatophagoides mixture is 3,000 mTU/mL. Inmunotek has found it convenient to define 1 mTU (Therapeutic Unit of mannan) as the result of polymerising and conjugating 10 biological units of the corresponding semi-purified native extract with mannan.
PlaceboBiological
The composition of the placebo IMP is as follows: • Identical in composition to the active IMP, but without active ingredients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score (RCSMS) by means of the Subject's DiaryTime frame: Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
Unidade Local de Saúde de Coimbra, EPE
Coimbra, Portugal · Not yet recruiting
Unidade Local de Saúde de São José, EPE
Lisbon, Portugal · Not yet recruiting
Unidade Local de Saúde de Santa Maria, EPE
Lisbon, Portugal · Not yet recruiting
Hospital CUF Descobertas
Lisbon, Portugal · Not yet recruiting
Unidade Local de Saúde de Santo António, EPE
Porto, Portugal · Not yet recruiting
Hospital CUF Porto
Porto, Portugal · Not yet recruiting
Hospital General Universitario Dr. Balmis
Alicante, Spain · Active not recruiting
H. Vithas Medimar
Alicante, Spain · Not yet recruiting
H. U. San Juan de Alicante
Alicante, Spain · Active not recruiting
Hospital Universitari Consorci Sanitari de Terrassa
Barcelona, Spain · Active not recruiting
Hospital Sant Joan de Déu Barcelona
Barcelona, Spain · Recruiting
Clínica Privada Dr. Barceló
Málaga, Spain · Recruiting
Hospital U. Regional de Málaga
Málaga, Spain · Recruiting
H. U. de Melilla
Melilla, Spain · Not yet recruiting
Hospital La Plana
Ciudad Real, Castellón, Spain · Not yet recruiting
H.U. de Canarias
San Cristóbal de La Laguna, Tenerife, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.